Ryvu Therapeutics

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

MoneyHero

MCap

USD60m

Last close

USD2.35

▲ 0.55 (30.56%)

MGI – Media and Games Invest

MCap

EUR235m

Last close

EUR1.50

▲ 0.35 (30.21%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Ryvu Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Healthcare |
Outlook

24.02.21

Ryvu Therapeutics — Rebalancing R&D pipeline towards clinical stage

Healthcare |
Update

11.05.20

Ryvu Therapeutics — Diversified pipeline ensures continued newsflow

Healthcare |
Update

23.03.20

Ryvu Therapeutics — Successful Phase I with SEL24/MEN1703

Healthcare |
Update

04.12.19

Ryvu Therapeutics — First ever clinical data from lead assets in 2020

Visit Website

Sector

Healthcare

Financials

Previously published reports can still be accessed via our website.

Outlook

Healthcare

28.11.17

Selvita — New 2017-2021 strategy to boost R&D

Flash note

Healthcare

09.10.17

Selvita — Clinical hold on SEL24

Flash note

Healthcare

28.03.17

Selvita — Menarini Group in-licensed SEL24

Outlook

Healthcare

20.03.17

Selvita — SEL24 enters Phase I/II

Update

Healthcare

22.11.16

Selvita — Update 22 November 2016

Update

Healthcare

14.10.16

Selvita — Update 14 October 2016

Update

Healthcare

22.08.16

Selvita — Update 22 August 2016

Update

Healthcare

17.06.16

Selvita — Update 17 June 2016

Update

Healthcare

25.04.16

Selvita — Update 25 April 2016

Outlook

Healthcare

09.12.15

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

Ryvu Therapeutics (WSE: RVU)

Latest Insights

Ryvu Therapeutics — Rebalancing R&D pipeline towards clinical stage

Ryvu Therapeutics — Diversified pipeline ensures continued newsflow

Ryvu Therapeutics — Successful Phase I with SEL24/MEN1703

Ryvu Therapeutics — First ever clinical data from lead assets in 2020

Sector

Financials

Selvita — New 2017-2021 strategy to boost R&D

Selvita — Clinical hold on SEL24

Selvita — Menarini Group in-licensed SEL24

Selvita — SEL24 enters Phase I/II

Selvita — Update 22 November 2016

Selvita — Update 14 October 2016

Selvita — Update 22 August 2016

Selvita — Update 17 June 2016

Selvita — Update 25 April 2016

Selvita — Update 8 December 2015